Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.56 USD

38.56
568,605

-0.40 (-1.03%)

Updated Oct 18, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN) Antibody Cocktail for COVID-19 Gets a Boost

by Zacks Equity Research

Regeneron (REGN) antibody cocktail for COVID-19 receives a boost as the Governor of Florida recommends it for COVID-19 treatment.

Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations

by Zacks Equity Research

Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.

Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication

by Zacks Equity Research

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.

Kinjel Shah headshot

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Merck's (MRK) VHL-Linked Tumor Drug Welireg Gets FDA Nod

by Zacks Equity Research

Merck's (MRK) Welireg (belzutifan) is the first and only systemic therapy approved for treating patients with certain types of von Hippel-Lindau (VHL) disease-associated tumors.

Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA

by Zacks Equity Research

Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.

Merck's (MRK) Keytruda/Lenvima Get FDA Nod for Kidney Cancer

by Zacks Equity Research

FDA approves Merck's (MRK) Keytruda + partenr Eisai's Lenvima for advanced RCC in the first-line setting based on data from the phase III CLEAR/KEYNOTE-581 study.

Merck's (MRK) Two Keytruda sBLAs Get Accepted by the FDA

by Zacks Equity Research

FDA likely to decide on Merck's (MRK) sBLA for Keytruda as an adjuvant therapy in certain patients with RCC on Dec 10 and in certain patients with MSI-H/dMMR advanced endometrial carcinoma on Mar 28, 2022.

Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance

by Zacks Equity Research

Halozyme (HALO) second-quarter earnings and sales beat estimates. The company raises 2021 guidance. Stock up.

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the second quarter of 2021 while revenues decline year over year. Stock up.

Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down

by Zacks Equity Research

Eli Lilly (LLY) reports mixed second-quarter results and ttightens 2021 sales forecast. Stock down in pre-market trading.

Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y

by Zacks Equity Research

Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.

Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline

by Zacks Equity Research

Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.

Kinjel Shah headshot

Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV

by Kinjel Shah

Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.

Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised

by Zacks Equity Research

Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.

Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track

by Zacks Equity Research

Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q2

by Zacks Equity Research

Glaxo (GSK) beats earnings as well as revenues estimates in the second quarter of 2021. Stock up.

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

by Zacks Equity Research

Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.

Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan

by Zacks Equity Research

Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.

Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance

by Zacks Equity Research

Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above market. Market recovery might have led to continued recovery in Medical Devices segment in the second quarter.

Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study

by Zacks Equity Research

Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.

Lilly (LLY) Stock Riding on Pipeline Developments This Year

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.